NYT: Johnson & Johnson to pay $33M to resolve claims over drug misrepresentation: 4 things to know

Johnson & Johnson will pay 42 states and Washington, D.C. $33 million through a settlement to resolve claims that the company misrepresented manufacturing practices for several of its over-the-counter drugs, according to The New York Times.

Advertisement

Here are four things to know:

1. In a news release, Illinois Attorney General Lisa Madigan said J&J recalled several medicines, including St. Joseph Aspirin, Sudafed, Pepcid, Mylanta, Rolaids, Zyrtec and Zyrtec Eye Drops.  Some of these drugs also included children’s medications.  

2. The states’ attorney generals said the company must also make sure that its marketing and promotional practices do not violate laws when promoting its over-the-counter drugs.

3. In the suit, the states claim McNeil-PPC, a J&J entity, put drugs on that market that violated federal standards, according to NYT.

In a statement, Illinois Attorney General Lisa Madigan said, “Johnson & Johnson’s disregard for proper manufacturing practices of children’s medications was unacceptable,” NYT reports.

4. J&J said the following in a statement, “recalls were precautionary and not undertaken on the basis of any health or safety risks to consumers, and we remain committed to providing consumers with safe and effective over-the-counter medicines.”

More articles on quality and infection control:
UCLA researchers detect antibiotic-resistant superbugs in 4 California parks
Unnecessary tests, treatment increased this LA practice’s complication risk by 29%, cost of care by 7%
Life expectancy varies by US county: 5 study findings

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

  • As the ASC industry continues to grow alongside new waves of surgical innovation, patient preferences and shifts to value-based care,…

  • A Pleasant View, Utah-based physician has been indicted on charges of obtaining unapproved drugs from China and selling them to…

  • From payer obstacles to operational pressures, five ASC leaders discuss the biggest frictions they’re facing. Note: Responses were lightly edited.…

Advertisement

Comments are closed.